In this report, we provide guidance for hyperglycemia management and monitoring strategies aimed at minimizing alpelisib dose disruption in patients with HR+, HER2−, PIK3CA-mutated advanced breast cancer. This evidence concerns the gene PIK3CA and breast carcinoma.